Achieve Life Sciences (NASDAQ:ACHV) Releases Earnings Results, Misses Estimates By $0.06 EPS

Achieve Life Sciences (NASDAQ:ACHV) issued its earnings results on Tuesday. The biopharmaceutical company reported ($0.36) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.30) by ($0.06), Zacks reports.

Achieve Life Sciences Stock Down 9.2 %

Shares of NASDAQ:ACHV opened at $2.65 on Thursday. The company has a debt-to-equity ratio of 0.31, a current ratio of 6.78 and a quick ratio of 6.78. The company has a market capitalization of $91.13 million, a PE ratio of -2.35 and a beta of 1.67. Achieve Life Sciences has a 1 year low of $2.65 and a 1 year high of $5.59. The business has a fifty day moving average price of $3.20 and a two-hundred day moving average price of $4.04.

Analyst Upgrades and Downgrades

A number of equities analysts have recently weighed in on the company. RODMAN&RENSHAW raised Achieve Life Sciences to a “strong-buy” rating in a research report on Thursday, November 14th. Rodman & Renshaw began coverage on Achieve Life Sciences in a research report on Thursday, November 14th. They issued a “buy” rating and a $12.00 price target for the company. Three analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, Achieve Life Sciences currently has a consensus rating of “Buy” and a consensus target price of $15.75.

Achieve Life Sciences Company Profile

Achieve Life Sciences, Inc, a clinical-stage pharmaceutical company, develops and commercializes cytisinicline for smoking cessation and nicotine addiction. The company offers cytisinicline, a plant-based alkaloid that interacts with nicotine receptors in the brain that reduce the severity of nicotine withdrawal symptoms.